canertinib dihydrochloride

Canertinib Dihydrochlorideis an irreversible tyrosine-kinase inhibitor with activity against EGFR HER-2 and ErbB-4 By 2015, Pfizer had discontinued development of the drug. It is an experimental drug candidate for the treatment of cancer. Canertinib Dihydrochloride has been reported as a substrate for OATP1B3.. Reference standards of Canertinib Dihydrochloride API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

stdClass Object
(
    [pname] => Canertinib Dihydrochloride - API Standards 
    [catalogue_number] => PA 03 08000
    [category_ids] => ,80,69,81,78,70,82,79,89,
    [chemical_name] => 
    [weight] => 558.86
    [form] => C24H27Cl3FN5O3
    [cas] => 289499-45-2
    [pslug] => 289499-45-2-canertinib-dihydrochloride-api-pa0308000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)